Ataxia telangiectasia screening

Revision as of 17:58, 13 June 2020 by Arash Moosavi (talk | contribs) (→‎References)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Ataxia telangiectasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ataxia telangiectasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ataxia telangiectasia screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ataxia telangiectasia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ataxia telangiectasia screening

CDC on Ataxia telangiectasia screening

Ataxia telangiectasia screening in the news

Blogs on Ataxia telangiectasia screening

Directions to Hospitals Treating Ataxia telangiectasia

Risk calculators and risk factors for Ataxia telangiectasia screening

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Screening

One of the defective screening test for newborn is severe combined immunodeficiency (SCID), which detect T cells and B cells deficiency or absence from infant dried blood spots. Although there is no modifying therapy or cure for A-T recently, SCID screening test allows for early family education and genetic counseling.
Pre-implantation genetic diagnosis (PGD) can avoid the birth of an affected child. By this screening test, parents who have an affected child (or children) with A-T take its advantages.
Antenatal diagnosis can also be performed using haplotype analysis if a diagnosis has been made for the affected child. In this case, DNA polymorphisms within and around the ATM gene can be utilized even if the pathogenic mutations are not known. [1]



References

Template:WH

Template:WS